Temporal trends in use of antisecretory agents among patients administered clopidogrel‐based dual antiplatelet therapy after percutaneous coronary intervention
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Yonghyuk Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Pusan National University, Busan, Republic of Korea. Hauptthemen laut MEDLINE: Clopidogrel, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Proton Pump Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antisecretory drugs are commonly prescribed with clopidogrel‐based dual antiplatelet therapy (DAPT) to prevent gastrointestinal bleeding in high‐risk patients after percutaneous coronary intervention (PCI). However, omeprazole and esomeprazole (inhibiting proton pump inhibitors [PPIs]) may increase cardiovascular event rates on co‐administration with clopidogrel. This study aimed to examine trends in the use of antisecretory agents in patients administered clopidogrel‐based DAPT and the concomitant use of clopidogrel and inhibiting PPIs.
Methods
We used National Inpatient Sample data compiled by the Health Insurance Review & Assessment Service from 2009 to 2020. Further, we identified patients who were prescribed clopidogrel‐based DAPT after PCI and investigated the concomitant use of antisecretory agents with clopidogrel. To verify the annual trend of drug utilization, we used the Cochran–Armitage trend test.
Results
From 2009 to 2020, the percentage of H2 receptor antagonist users decreased steadily (from 82.5% in 2009 to 25.3% in 2020); instead, the percentage of PPI users increased (from 23.7% in 2009 to 82.0% in 2020). The use of inhibiting PPI also increased (from 4.2% in 2009 to 30.7% in 2020). Potassium competitive acid blockers (P‐CABs) were rarely used before 2019; however, in 2020, it accounted for 7.8% of the antisecretory users.
Conclusions
Our study demonstrates that the use of inhibiting PPIs increased steadily in patients administered clopidogrel‐based DAPT therapy. This is a major concern since the concomitant use of inhibiting PPIs with clopidogrel could increase the risk of cardiovascular events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Pusan National University, Busan, Republic of Korea.
- College of Pharmacy, Woosuk University, Wanju, Republic of Korea.
- Research Institute for drug development, Pusan National University, Busan, Republic of Korea.
ORCID-Profile: Nam Kyung Je
Zitieren
APA
Lee, Y., Choi, H. J., Park, S., & Je, N. K. (2024). Temporal trends in use of antisecretory agents among patients administered clopidogrel‐based dual antiplatelet therapy after percutaneous coronary intervention. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5816
Vancouver
Lee Y, Choi HJ, Park S, Je NK. Temporal trends in use of antisecretory agents among patients administered clopidogrel‐based dual antiplatelet therapy after percutaneous coronary intervention. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5816
BibTeX
@article{Lee2024,
author = {Lee, Yonghyuk and Choi, Hye-Jeong and Park, Susin and Je, Nam Kyung},
title = {Temporal trends in use of antisecretory agents among patients administered clopidogrel‐based dual antiplatelet therapy after percutaneous coronary intervention},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5816}
}
EUVIMED